STOCK TITAN

ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

ADMA Biologics (Nasdaq: ADMA) has announced it will report its third quarter 2024 financial results on November 7, 2024, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Participants can dial (888) 596-4144 with conference ID 2959956 to join the call. A webcast will be available for those not asking questions, and an archived replay will be accessible through the company's investor relations website.

ADMA Biologics (Nasdaq: ADMA) ha annunciato che comunicherà i suoi risultati finanziari del terzo trimestre 2024 il 7 novembre 2024, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e una trasmissione audio in diretta alle 16:30 ET lo stesso giorno. I partecipanti possono comporre il numero (888) 596-4144 con ID conferenza 2959956 per partecipare alla chiamata. Sarà disponibile una trasmissione per coloro che non fanno domande, e una registrazione archiviata sarà accessibile tramite il sito web delle relazioni con gli investitori dell'azienda.

ADMA Biologics (Nasdaq: ADMA) ha anunciado que reportará sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024, después del cierre del mercado estadounidense. La compañía llevará a cabo una llamada de conferencia y una transmisión de audio a las 4:30 p.m. ET el mismo día. Los participantes pueden marcar el número (888) 596-4144 con el ID de conferencia 2959956 para unirse a la llamada. Habrá una transmisión disponible para aquellos que no formulen preguntas, y una repetición archivada estará accesible a través del sitio web de relaciones con inversores de la empresa.

ADMA Biologics (Nasdaq: ADMA)는 2024년 11월 7일 미국 시장이 마감된 후 2024년 3분기 재무 결과를 보고할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜 및 오디오 웹캐스트를 주최할 예정입니다. 참가자는 전화 (888) 596-4144로 전화 회의 ID 2959956을 입력하여 콜에 참여할 수 있습니다. 질문을 하지 않는 분들을 위한 웹캐스트가 제공되며, 아카이브된 재생은 회사의 투자자 관계 웹사이트를 통해 접근할 수 있습니다.

ADMA Biologics (Nasdaq: ADMA) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le 7 novembre 2024, après la clôture du marché américain. L'entreprise organisera une conférence téléphonique et un webcast audio à 16h30 ET le même jour. Les participants peuvent composer le (888) 596-4144 avec l'ID de conférence 2959956 pour rejoindre l'appel. Un webcast sera disponible pour ceux qui ne posent pas de questions, et une rediffusion archivée sera accessible via le site de relations avec les investisseurs de l'entreprise.

ADMA Biologics (Nasdaq: ADMA) hat angekündigt, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 am 7. November 2024 nach Börsenschluss in den USA bekannt geben wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Audio-Webcast veranstalten. Teilnehmer können die Nummer (888) 596-4144 mit der Konferenz-ID 2959956 wählen, um an dem Anruf teilzunehmen. Für diejenigen, die keine Fragen stellen, wird ein Webcast verfügbar sein, und eine archivierte Wiederholung wird über die Website der Investor Relations des Unternehmens zugänglich sein.

Positive
  • None.
Negative
  • None.

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call, please dial (888) 596-4144 and refer to conference ID 2959956. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com


FAQ

When will ADMA Biologics (ADMA) report Q3 2024 earnings?

ADMA Biologics will report its third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close.

What time is ADMA Biologics Q3 2024 earnings call?

ADMA Biologics will host its Q3 2024 earnings conference call on November 7, 2024, at 4:30 p.m. ET.

How can I join ADMA Biologics Q3 2024 earnings call?

You can join by dialing (888) 596-4144 with conference ID 2959956, or listen to the live webcast through ADMA's investor relations website.

ADMA Biologics, Inc.

NASDAQ:ADMA

ADMA Rankings

ADMA Latest News

ADMA Stock Data

4.98B
227.22M
2.55%
90.78%
6.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
RAMSEY